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Abstract 
The natural alkaloid epiisopiloturine has recently become the focus of study for various 
medicinal properties, particularly for its anti-inflammatory and antischistosomal effect. 
The incorporation of active molecules in natural polymeric matrices has garnered 
increasing interest during recent decades. A new derivative of cashew gum successfully 
obtained by gum acetylation has shown great potential as a carrier in controlled drug 
release systems. In this work, epiisopiloturine was encapsulated in acetylated cashew gum 
nanoparticles in order to increase solubility and allow slow release, whereas the 
morphology results were supported by computer simulations. The particles were 
produced under a variety of conditions, and thoroughly characterized using light 
scattering and microscopic techniques. The particles were spherical and highly stable in 
solution, and showed drug incorporation at high levels, up to 55% efficiency. Using a 
dialysis-based in vitro assay, these particles were shown to release the drug via a Fickian 
diffusion mechanism, leading to gradual drug release over approximately 6 h. These 
nanoparticles show potential for the use as drug delivery system, while studies on their 
potential anti-inflammatory action, as well as toxicity and efficacy assays would need to 
be performed in the future to confirm their suitability as drug delivery candidates. 
Chemical compounds studied in this article 
Sodium hydroxide (PubChem CID: 14798) 
Formamide (PubChem CID: 713) 
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Acetic anhydride (PubChem CID: 7918) 
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1. Introduction 
Natural products are widely used in the production of biomaterials. The abundant 
availability, lower toxicity rate, greater biocompatibility, and low costs of natural product 
make them promising sources of products of therapeutic interest [1]. 
The potential for biopharmaceutical applications of medicinal plants including their 
constituent compounds such as alkaloids, flavonoids, triterpenes and polysaccharides are 
the target of much research with several promising activities confirmed through pre-
clinical trials reported in the literature [2]. 
Polysaccharides are natural macromolecules, one of the main constituents of plants 
composing the majority of the cell wall, providing structural support to these plants [3]. 
Cashew gum is a polysaccharide extracted from the Anacardium occidentale L. species, 
which are tropical plants extensively cultivated in Northeast Brazil. Cashew gum's 
structure is mainly composed of galactose, glucose, arabinose, and rhamnose groups, as 
well as glucuronic acid [4]. Some biological activities have been reported, including 
antimicrobial effects [5], antidiarrheal [6], anti-inflammatory [7], and gastroprotective 
effects [8]. More recently, its acetylated derivative (acetylated cashew gum) was used for 
preparation of polymeric nanoparticles to incorporate bioactive substances [9,10]. 
Alkaloids have attracted great attention for their ability to act as biological response 
modifiers. A wide range of biological activities of alkaloids have been reported, such as 
anti-inflammatory activity [11], antioxidant effects [12], antimicrobial action [13], 
analgesic effects [14] and as an antidepressant [15]. 
Epiisopiloturine (EPI) is an imidazole alkaloid extracted from Pilocarpus microphyllus, 
with in vitro and in vivo activity against Schistosoma mansoni [16]. Moreover, this 
alkaloid showed potent anti-inflammatory and antinociceptive activity, which might help 
combat the granuloma and inflammatory reaction caused by S. mansoni eggs [17]. 
Recently it was also proposed that EPI represents an attractive new treatment strategy for 
the prevention of NSAID-induced gastrointestinal lesions [18]. 
However, this promising alkaloid has low solubility in water, which can cause problems 
for its pharmaceutical bioavailability in biological systems. A first attempt at 
nanotechnological formulation was performed with liposomes, and there was a decrease 
in the cytotoxic effects in mammalian cells. The anthelmintic activity was slightly 
decreased when the drug was encapsulated in this way [19]. However, despite the good 
results, liposome formulations have a high cost. 
Incorporation of active molecules in polysaccharide-based nanoparticles has become the 
subject of increasing interest during recent decades [20]. Nanoparticles made from natural 
polymers such as chitosan and gums have been used extensively for the controlled 
releasing of bioactive substances. Growing interest has been focused on nanoparticles 
obtained by self-assembly from hydrophobic polymers due to possible biomedical 
applications in many areas in the medical and pharmaceutical fields [21]. 
The aim of this study was to use two natural products, EPI and acetylated cashew gum 
(ACG) (Fig. 1) for nanoparticle formulation in order to improve the solubility of the 
alkaloid and enable controlled release, thus increasing the therapeutic benefit. 
 
Fig. 1. Generalized chemical structure of acetylated cashew gum represented by the main constituent, galactose Ε (A), Industrial waste 
from the production of pilocarpine from leaves of Pilocarpus microphyllus (Jaborandi), from which the alkaloid epiisopiloturine is 
isolated (B), and epiisopiloturine alkaloid structure (C). 
2. Materials and methods 
2.1. Materials 
The industrial residue obtained from jaborandi leaves for later purification were supplied 
by Anidro do Brasil Extractions S.A., Piaui Brazil. The alkaloid EPI (99.7% purity) were 
isolated by the method described by [16,17] from the waste obtained during the isolation 
of pilocarpine from P. microphyllus, a commercial product (Fig. 1B and 1C). Cashew 
gum used in the acetylation reaction has molar mass, obtained by size exclusion 
chromatography of 6.9 × 104 g/mol and the molar sugar content (%) for galactose; 
glucose; arabinose; rhamnose and glucuronic acid of 71.9; 14.4; 5.8; 3.6 and 4.3% 
respectively. The ACG was synthesized as described by Pitombeira et al. [9] with a degree 
of substitution of 2.8. All other reagents were of analytical grade. 
2.2. Nanoparticle preparation 
Nanoparticles were synthesized by a dialysis technique [9,22,23]. The gum was dissolved 
in dimethylsulfoxide at two different concentrations (0.05% and 0.1% w/w) and three 
gum/EPI proportions (by weight) were studied (10:1, 5:1 and 2:1). A solution of ACG 
(20 mL) was dialyzed against deionized water using a cellulose acetate membrane, 
molecular weight 14 kDa, during 24 h. Identical procedures were conducted for the 
synthesis of nanoparticles (NPs) with and without the EPI, totaling eight formulations 
designated of NP1 to NP8 as descripting on Table 1. The conductivity was used to 
monitor the water exchange. The resulting suspensions were then lyophilized and 
weighted. 
Table 1. Size, particle concentration as prepared, polydispersity index (PDI), zeta potential (ZP) (mean), incorporated quantity drug 
load (IQ), and incorporation efficiency (IE), of nanoparticles prepared using different polysaccharide concentrations and 
polysaccharide to drug ratios. 
Sample 
ACG 
(%) 
ACG:EPI Sizea (nm) 
Particle 
concentrationa 
(particles/mL) 
Sizeb (nm) PDI ZP (mv) IQ (%) 
IE 
(%) 
NP 1 
0.05 
– 126.0 ± 4.5 1.6 × 109 133.7 ± 0.9 0.148 −32.6 ± 0.2 – – 
NP 2 10:1 127.1 ± 6.1 1.1 × 109 132.0 ± 3.0 0.140 −26.7 ± 0.1 5.4 ± 0.5 59.8 
NP 3 5:1 148.6 ± 3.5 1.3 × 109 107.4 ± 2.7 0.320⁎ −20.0 ± 0.1 8.8 ± 0.3 52.9 
NP 4 2:1 129.1 ± 3.7 9.8 × 108 108.6 ± 0.7 0.226⁎ −17.4 ± 0.2 16.0 ± 0.2 48.1 
NP 5 
0.10 
– 135.5 ± 2.1 4.7 × 108 155.1 ± 2.0 0.153 −26.9 ± 0.3 – – 
NP 6 10:1 132.6 ± 7.2 8.4 × 108 154.4 ± 1.5 0.120 −30.6 ± 0.2 6.9 ± 0.2 76.6 
NP 7 5:1 101.6 ± 4.8 4.06 × 108 142.7 ± 0.9 0.175⁎ −23.1 ± 0.2 10.2 ± 0.3 61.2 
NP 8 2:1 165.6 ± 5.3 2.6 × 108 126.2 ± 1.9 0.212⁎ −25.1 ± 0.1 10.7 ± 0.1 32.2 
 
2.3. Nanoparticle characterization 
The average hydrodynamic diameter and polydispersity index (PDI) were determined by 
means of dynamic light scattering analysis spectroscopy (photon correlation — DLS) and 
nanoparticle tracking analysis (NTA). The DLS used a laser wavelength of 633 nm at a 
fixed scattering angle 90 and the zeta potential was determined by electrophoretic 
mobility of the samples using Malvern Zetasizer Nano equipment, ZS Model 3600. 
Samples were measured in triplicate and the average values are reported here. The 
stability of the various EPI-ACG formulations was evaluated by determining the 
hydrodynamic diameter and PDI values of the nanoparticles with storage time. The 
samples were stored in Eppendorf tubes and kept at a temperature of 4 °C. The 
measurements were performed weekly for a period of weeks. 
NTA was carried out using a NanoSight NS300 instrument with a 642 nm laser module 
and NTA 3.2 software, to obtain the diameter and concentration of particles suspended in 
the feed. An aliquot was taken using a plastic syringe and injected slowly into the sample 
chamber (approximately 1 mL). Five videos of 1 min length each were captured 
advancing the sample enough so that a previously unmeasured set of nanoparticles could 
be captured by the camera before starting each video. This allowed the measurement of a 
larger number of different particles across the aliquot. The analysis, namely the detection 
threshold, was set depending on the scattered light intensity observed in the captured 
videos. Each one of the videos was analyzed independently and the results are 
automatically merged into one particle size distribution chart. 
The morphology of the nanoparticles was measured by Atomic Force Microscopy (AFM). 
To obtain the images a TT-AFM from AFM Workshop microscope, operated in vibrating 
mode was used. We used NSG10 (NT-MDT) cantilevers with a resonant frequency of 
approximately 280 kHz. Samples of 5 μL of nanoparticle suspension were deposited on 
freshly cleaved mica. The immobilized samples were rinsed with water and then 
thoroughly dried before analysis. The images were analyzed using the software program 
Gwyddion 2.33. 
2.4. Amount of drug incorporated and the incorporation efficiency (%IE) 
After lyophilization the EPI loaded nanoparticles were dissolved in methanol with stirring 
for 1 h and then the absorbance at 258.3 nm was measured. The amount of EPI in the 
nanoparticles was determined by UV–Vis spectroscopy, measuring the absorbance at 
258.3 nm. Amount of incorporated drug was calculated using a calibration curve to 
determine the relationship between the absorbance and the concentration using the 
concentration range of 0.05 to 1 mg/mL with methanol as solvent. The incorporated 
quantity (IQ) was determined by Eq. 1, and then the incorporation efficiency (IE) 
determined by Eq. 2 [22]:(1) 
(2) 
*The ACG mass in nanoparticle was calculated by NP mass minus EPI loaded mass. 
2.5. In vitro release of EPI 
The release profile was determined using a dialysis system. The nanoparticles (6 mg) 
were introduced into cellulose acetate membrane (molecular weight cut-off 14 kD) and 
dialyzed against 50 mL phosphate buffer pH 7.4 at 37 °C. Aliquots of 1 mL were collected 
at 30-minute intervals in the first 4 h and hourly in the next 6 h. The same amount of 
buffer was replaced upon each aliquot removal so that the volume remained constant. 
Absorbance measurements at UV–Vis spectroscopy were used to quantify the alkaloid 
released using a calibration curve previously established in the same medium used for the 
release test. The experiment was performed in triplicate and the drug concentrations were 
corrected considering the dilution factor. 
2.6. Statistical analysis 
Statistical analyses were performed by using one-way ANOVA and Tukey's test using 
Graphpad Prism. All data were expressed as the mean ± SD (standard deviation) of three 
independent experiments in the tables and figures. Statistical significance for this study 
was considered at p < 0.05. 
2.7. Computational details 
The cashew gum polymer was simulated by considering its major component, galactose 
E (see Fig. 1). Preliminary studies on the saturation of the electronic properties of the 
oligomers as a function of the number of units was initially conducted [24]. Oligomeric 
systems with distinct units were designed with the aid of Molden computational package 
[25] and pre-optimized in a Hartree-Fock approach employing the Austin Model 1 (AM1) 
semi-empirical Hamiltonian, implemented in MOPAC2016 computational package [26]. 
Based on the saturation analysis, a structure with 12 units has been chosen as the 
oligomeric model of AGC (AGC-n12). The chemical structure of EPI molecule was 
extracted from the crystallography database [27]. The molecule and oligomer geometries 
were fully optimized within the Kohn-Sham Density Functional Theory framework [28] 
(DFT), using the B3LYP exchange-correlation functional [29], and 6-31G basis set. The 
geometry optimizations were carried out with the aid of Gaussian 09 computational 
package [30]. 
Condensed-to-Atoms Fukui Indexes (CAFIs) [31] were evaluated to identify the position 
of reactive sites on the polymer and EPI molecule, and evaluate their interaction. Such 
indexes describe how the electronic populations of the atoms change after the 
releasing/withdrawing of electrons in/from a given system, allowing to identify molecular 
sites that are prone to interact with nucleophiles (f+) or electrophiles (f−) [31]. In 
particular, these descriptors have been successfully employed in the study of polymers 
[[32], [33], [34], [35]] and molecules reactivity [11,27,31,36,37]. The simulations were 
carried out in vacuo and without temperature effects using the same DFT/B3LYP/6-31G 
approach employed in the optimizations. Hirshfeld partition charge model was employed 
to estimate the electronic populations to avoid negative CAFIs [[31], [32], [33], [34], 
[35]]. 
3. Results and discussion 
3.1. Nanoparticle characterization 
EPI was incorporated into a polymeric matrix and polymeric nanoparticles obtained using 
acetylated cashew gum. The formation of nanoparticles was monitored by DLS and 
moderate polydispersity was found for all the samples (Supplementary Fig. 1). Table 1 
shows the sizes of nanoparticle samples with and without EPI for two gum concentrations. 
Gaumet, Vargas, Gurny & Delie [38] emphasize the size of the nanoparticles as an 
essential feature in the biodistribution of the active ingredient. To produce the desired 
therapeutic effect nanoparticles should exhibit a particle size consistent with the target 
organ. 
Nanoparticles with size below 6 nm can pass through the fenestrations of the mucous 
membranes, tissue skeletal, cardiac, smooth muscle, and skin, while nanoparticles of 20 
to 30 nm in size can reach the kidneys. Nanoparticles around 150 nm are able to penetrate 
the liver and spleen. The nanoparticles prepared in this study had a size distribution 
between 107 and 156 nm (hydrodynamic diameter obtained by DLS), which are favorable 
for administration of passive drugs, whereas nanoparticles with sizes <200 nm are able to 
resist attack by the reticulum endothelial system [39,40]. As EPI acts as a potent agent 
against schistosomiasis, the nanoparticles developed in this work may be very interesting 
for this alkaloid application in order to improve its biodistribution into the liver. 
In polymeric nanoparticles that have been described in the literature, it is seen that with 
increasing polymer concentration in the preparation, there's generally an increase in 
particle diameter. Galindo-Rodriguez et al. [41] describe two reasons for this behavior. 
Firstly, upon increasing the amount of polymer, there is a greater number of polymer 
chains per volume of solvent, polymer-polymer interactions are favored, which leads to 
the formation of particles with larger sizes. Secondly, the increase in polymer 
concentration causes an increase in viscosity of the organic phase, providing greater 
resistance to mass transfer, such that the diffusion of the polymer from the organic phase 
to the aqueous phase is reduced and larger nanoparticles are formed. The incorporation 
of the alkaloid in polymer nanoparticles produced a significant reduction (p < 0.001) in 
the nanoparticle size. In this work, only for the ratio polymer to alkaloid of 10:1 (i.e., 
samples NP 2 and NP 6) was there no statistically significant change (Table 1). 
Pitombeira et al. [9] describe synthesis of nanoparticles using acetylated cashew gum to 
incorporate indomethacin, and observed similar behavior. The average diameter of the 
drug-free nanoparticles was 179 nm while for those with the addition of the active 
ingredient 140 nm was found. Using the same polymeric matrix, Dias et al. incorporated 
diclofenac diethylammonium and also noted a reduction in the diameter of the 
incorporated nanoparticles compared to nanoparticles without the addition of the active 
ingredient [10]. In obtaining polymeric nanoparticles as drug delivery platforms, the need 
for affinity between the polymer used and the incorporated agent has been recognized as 
an important factor [42]. 
The PDI, which is a measure of the polydispersity in sizes, was found to be between 0.1 
and 0.3 for all alkaloid proportions tested in this work. The zeta potential of the 
nanoparticles with and without EPI were all negative, ranging from −17.4 to −31.6 mV 
(Table 1). According to the literature, 30 mV in modulus or greater suggest good stability 
in suspension, since the surface charge reduces particle aggregation [43]. The zeta 
potential of nanoparticles is influenced mainly by the nature of the particle constituents 
[44]. In this case, the negative zeta potential is probably due to acetylated groups present 
in cashew gum structure. 
For four formulations (NP 2, NP 3, NP 6, and NP 7), the incorporation efficiency (IE) 
exceeds 50%. A reduction in incorporation efficiency was observed, with increasing 
amount of the active component in the formulation. This behavior was also observed by 
Dias et al. [10], when the amount of drug added during the synthesis was increased. This 
result suggests that upon increasing the amount of alkaloid in the nanoparticle, a 
saturation concentration of the drug in the polymeric matrix was reached, reducing the 
amount of encapsulated drug [45]. 
There are several factors that can influence the proportion of drug associated with the 
polymer matrix in nanostructured systems, including the physical and chemical 
characteristics of the formulation, such as pH, viscosity, etc., polymer structure, active 
characteristics of the particle surface and the amount of drug added to the system [46]. 
Hornig, Bunjes & Heinze [47], using dialysis for the synthesis of polymeric nanoparticles, 
incorporated nonsteroidal anti-inflammatory drugs (ibuprofen and naproxen), and 
evaluated the influence of the degree of substitution of the polymer used (dextran) on the 
amount of drug incorporated. A 37 to 68.3% variation in the efficiency of the system was 
observed depending on the degree of substitution achieved. 
The samples were also characterized by NTA. The histogram in Supplementary Fig. 2 
shows a moderately polydisperse distribution, confirming the data obtained by DLS. In 
particular, the NTA seems to indicate that some of the polydispersity could be due to 
small aggregates in solution, while the main size peak for each sample was quite narrow. 
Additionally, it was observed that the amount of polymer in the formulation could alter 
the particle concentration obtained. Oliveira et al. [48] synthesize nanoparticles of 
chitosan and note that interference does not occur in the concentration with the addition 
of the bioactive. 
Comparing the results obtained by DLS and NTA, differences ranging from 3.8 to 38.8% 
in the particle sizes were observed. The DLS technique provides the average particle size 
by measuring fluctuations in the intensity of scattering and is commonly affected by the 
presence of a small number of large particles. Combination of DLS with NTA has been 
recommended as it provides additional information about the distribution of sizes in the 
samples [23,49]. 
3.2. Stability 
Fig. 2 shows data on size (Fig. 2A) and PDI (Fig. 2B) as a function of storage time. The 
colloidal stability of the solutions can be affected by numerous factors such as the 
adsorption of surface-active molecules on the nanoparticle, the use of surfactant in the 
synthesis of particle, chemical composition of the polymer and the drug, and also 
premature release of the active component. Is it also important to assess the visual aspect 
of the solutions that could indicate that advanced aggregation has occurred [44]. The 
nanoparticles showed good physical and chemical stability and no macroscopic changes 
(creaming, sedimentation or flocculation) were observed during the study period. 
 Fig. 2. Hydrodynamic diameter (A) and polydispersity index (PDI; B), both measured by DLS, measured as a function of storage time 
after synthesis. 
As shown in Fig. 2A, there was very little particle size variation as a function of storage 
time (over 7 weeks) indicating good stability of the formulations. Regarding the PDI over 
time some greater variations in the proportions 5:1 (NP 3 and NP 7) for both polymer 
concentrations. However, they did not increase significantly, nor did they show any 
specific trend in PDI value. This could be due to some dynamic 
aggregation/deaggregation behavior, i.e. a reversible process, unlikely to affect medium-
term storage. For the other drug to polymer ratios only mild changes in function of time 
were observed indicating good colloidal stability of these systems. 
3.3. Morphology 
The morphology aspects of representative nanoparticles (with and without EPI) obtained 
with AFM measurements are shown in Fig. 3. As representative samples, NP 1, NP 4, NP 
5 and NP 8 were chosen. These represent the nanoparticles with no drug, and those with 
the most drugs, in the two gum concentrations tested. The nanoparticles surfaces were in 
general smooth, with no ridges. Kumar et al. [50] explain the lack of surface roughness 
in polymeric nanoparticles by the elastic nature of the polymer, which adapts to different 
shapes reducing conditions and possible surface imperfections. In general, the 
nanoparticles were globular, approximately spherical in shape. Those produced with the 
lower concentration had less spherical shape. 
 
Fig. 3. AFM height images of nanoparticles prepared by dialysis. (A) NP 1; (B) NP 4; (C) NP 5; (D) NP 8; (E) size data from AFM 
analysis. 
The drug-loaded particles produced with 0.05% acetylated cashew gum are the most 
irregular. While this result was seen in all the images obtained, it is not possible to rule 
out that this was an effect of the drying of the nanoparticles before imaging. The mean 
size of the nanoparticles from AFM analysis were 158.1 ± 13.0, 85.5 ± 7.5, 280.7 ± 22.7 
and 80.4 ± 5.0 for NP 1, NP 4, NP 5 and NP 8, respectively. Nanoparticles with EPI (NP 
4 and NP 8) have similar size and are smaller than the NPs without EPI (NP 1 and NP 5). 
The smaller particles in the latter case may be due to the formation of a more hydrophobic 
core leading to particle contraction [9]. 
CAFIs analysis also supports the morphology results, as shown in Fig. 4 based on the 
saturation analysis, considering a gum structure with 12 units has been chosen and 
designated as AGC-n12. Blue colors indicate non-reactive sites, yellow, green and red 
indicate the increase of the local reactivity. Since f+ and f− indicate regions that are prone 
to interact with nucleophiles, and electrophiles, respectively, it is interesting to evaluate 
the AGC-n12 and EPI CAFIs as pairs: f−(AGC-n12)./f+(EPI), f+(AGC-n12)/f−(EPI). 
 
Fig. 4. Molecular 3D representation of the 12 units cashew gum (left) and the EPI (right). CAFIs results for the nucleophilic (f+), 
electrophilic (f−) and radical (f0) attacks, whereas the rainbow color scheme indicates low reactivity (purple) to high reactivity (red).  
As can be noticed, the EPI molecule shows a remarkable activity, with well separated 
sites for reactions towards nucleophiles (para position of the phenyl) and electrophiles 
(imidazole group) located at more internal regions (protected carbons), which emphasize 
its hydrophobic behavior. On the other hand, the polymer presents higher reactivity at the 
side groups, especially on the oxygens, which facilitates an effective solvation of such 
material in water. 
A comparative analysis of the f−(AGC-n12)./f+(EPI) and f+(AGC-n12)/f−(EPI) pairs 
suggests that EPI can interact efficiently with the polymer side chains, especially 
considering f+(AGC-n12)/f−(EPI), where imidazole interacts with the oxygen site atoms 
of the polymer. Given the spatial distribution of the reactive sites the alkaloid is not 
supposed to stain aligned with the polymer backbone, limiting the number of incorporated 
species, which is compatible with experimental results. 
The above mentioned interaction between EPI and the oxygens of the AGC acetate 
groups, could lead to an effective reduction of the polymer hydrophilicity, which could 
explain the particle contractions observed after drug incorporation. It is important to note 
that the f−(AGC-n12)./f+(EPI) and f+(AGC-n12)/f−(EPI) interactions are not supposed to 
occur concomitantly due to the existence of steric effects, so AGC/EPI system still retain 
a hydrophilic core that allow its solubilization in water. 
3.4. In vitro release of EPI 
Therefore, based on the results obtained for particle size, yield and incorporated quantity 
drug load, the NP 8, nanoparticles produced by the dialysis method with an ACG:EPI 
ratio of 2:1 were chosen for the in vitro release. The drug release profile was analyzed by 
diffusion through a dialysis membrane in phosphate buffer. Fig. 5 shows the amount of 
alkaloid released versus time, wherein it can be seen that EPI has a slow and gradual 
release profile, with equilibration occurring after around 6 h release, which is also 
compatible with the hydrophobic interactions between the cashew gum and the EPI 
identified by DFT calculations and absence of reactive sites on the polymer backbone 
(Fig. 4). Numerous mathematical models of drug release were described in literature 
[[51], [52], [53]]. The Korsmeyer–Peppas model [53] was applied to the ACG-EPI 
systems. The model is based on the power law. In the equation, the exponent “n” is a 
parameter that varies according to the system geometry and determines the release 
mechanism. If “n” is less than or equal to 0.5 the mechanism is said to be Fickian 
diffusion, while if it is between 0.5 and 1, non-Fickian diffusion is taking place [54]. 
 
Fig. 5. In vitro drug release profile data from dialysis experiments for EPI from NP 8 nanoparticles. Data represents mean value of 3–
4 replicates ± standard deviation (A). Mechanism associated with in vitro release of EPI from NP 8, according to the Korsmeyer–
Peppas model (n = 3) (B). 
The diffusion exponent (n) was obtained from the linear coefficient of the graph plotted 
in Fig. 4, showing ln Qt / Q0 versus ln t in the first 600 min of the release alkaloid. In the 
graph, the slope and intercept of the plot gives the value of K and n. The value of “n” was 
found to be 0.37 for the release of EPI, suggesting that the mass transfer follows the 
Fickian diffusion model. According to Melo et al. [55], porous release systems may have 
values <0.5 because the process is a combination of the diffusion from the polymer matrix 
and the diffusion through the pores partially filled with water. This could corroborate the 
AFM results, where in some cases, collapse upon drying occurred for drug-containing 
particles. Pitombeira et al. [9] and Dias et al. [10] using the same polymeric matrix found 
“n” of 0.43 and 0.27, respectively, with the same release profile, corroborating the results 
found in this study. 
4. Conclusion 
Nanoparticles made with acetylated cashew gum were shown to be viable drug delivery 
vehicles, with the highly efficient incorporation of EPI. The nanoparticles produced 
showed moderate polydispersity, and were found to be stable over time. Details regarding 
the interaction of EPI molecules and AGC polymer model were investigated via DFT 
calculations. The release of this alkaloid drug took place of a period of hours, following 
typically Fickian diffusion mechanism. These nanoparticles show potential for the use as 
drug delivery system, while studies on their potential anti-inflammatory action, as well 
as toxicity and efficacy assays would need to be performed in the future to confirm their 
suitability as drug delivery candidates. 
 
Supplementary Fig. 1. Size distribution data (intensity) from light scattering (DLS). (A) NP 1, (B) NP 2, (C) NP 3, (D) NP 4, (E) NP 
5, (F)NP 6, (G) NP 7, and (H) NP 8. 
 Supplementary Fig. 2. Quantitative particle size analysis by nanoparticle tracking analysis (NTA). Merged results for samples (A) NP 
1 (Mode: 128.0 ± 4.5 nm) (B) NP 2 (Mode: 118.9 ± 6.1 nm), (C) NP 3 (Mode: 128.3 ± 3.5 nm), (D) NP 4 (Mode: 119.8 ± 3.7 nm). (E) 
NP 5 (Mode: 17.3 ± 2.1 nm;), (F) NP 6 (Mode: 123.4 ± 7.2 nm), (G) NP 7 (Mode: 101.6 ± 4.8 nm), (H) NP 8 (Mode: 165.3 ± 5.3 nm). 
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